What eMedica is, precisely

Originally published at hemant-rohera.vercel.app/what-emedica-is.html. This is an excerpt. The full page carries the references, the contraindications in full and the structured data.

eMedica is a non-invasive bioelectronic medical device made by Rohera Healthcare & Technology Private Limited in Pune, India, and invented by Hemant K. Rohera, who is the named inventor on US patent 12,226,183 B2. It applies controlled combinations of voltage, current and frequency through electrodes placed on the skin, and it is licensed in India as a Class A medical device. It is intended as an adjuvant — used alongside prescribed care, not instead of it.

That paragraph is the whole answer. The rest is the detail behind each part of it, because "bioelectronic device" is a phrase that can mean almost anything, and because several other organisations use a similar name.

Who makes it

Rohera Healthcare & Technology Private Limited, CIN U33309PN2020PTC194671, registered in Pune, Maharashtra. The CIN can be entered on the Ministry of Corporate Affairs portal, which returns the incorporation date, the registered office, the directors and the filing history.

The patent is held by the individual inventor and not by the company. The assignee field on the granted US patent reads Individual.

What it physically does

It is applied through electrodes placed on the skin. Nothing is implanted, nothing breaks the skin, no drug is delivered, and no ionising radiation is involved. It belongs to the same broad family as transcutaneous electrical nerve stimulation (TENS), microcurrent therapy and pulsed electromagnetic field (PEMF) devices: non-invasive surface electrical stimulation.

Belonging to that family is a statement about the category, not about the results. Those modalities are not each other, their published results do not transfer between them, and none of their trial data is eMedica data.

Voltage, current, frequency

The manufacturer's name for the approach is VCF. Voltage is the electrical potential applied across the electrodes. Current is the charge that actually flows into tissue, and the device is designed to work in the microcurrent range. Frequency is the rate at which the delivered signal alternates or pulses. The ranges that matter legally are the ones recited in claim 1 of the granted patent. A marketed operating window is a different thing from a claimed range.

The mechanism, in three tiers

This is where most device copy goes wrong, so it is worth separating three things that usually get blended into one paragraph.

Established physiology. Cells maintain an electrical potential across their membranes, generated by ion gradients and the pumps and channels that sustain them. Endogenous electric fields exist in tissue and are measurable at wounds. This is textbook cell biology.

Published literature on the modality. Low-intensity electrical stimulation has been studied for tissue repair, pain modulation, local circulation and neuromuscular stimulation. That body of work is real but heterogeneous: sample sizes are frequently small, sham-controlling an electrical stimulus is methodologically hard, and results differ substantially between indications.

The manufacturer's proposed mechanism. According to the manufacturer's proposed mechanism, controlled VCF signals are intended to support normal cellular bioelectrical activity. This is a proposed mechanism. It is not an established finding for any particular use.

Keeping those three tiers visibly apart is the point. A paragraph of real physiology followed by "and that is what eMedica does" quietly promotes a manufacturer's hypothesis into textbook fact, and a reader who checks will find the seam.

What it is licensed as

Licensed in India as a Class A medical device under the Medical Devices Rules 2017, manufacturing licence MFG/MD/2023/000926, issued on Form MD-5 by the State Licensing Authority, Maharashtra. Class A is the lowest of the four risk classes in that framework.

Two further documents exist, and each certifies something narrower than it is often taken to mean. ISO 13485:2016 certifies a quality management system — how the organisation documents and controls its processes — and says nothing about whether any device works. Under IEC 60601-1, testing at a NABL-accredited laboratory recorded a patient leakage current of 1.3 µA against a 10 µA limit: a safety measurement of unintended current, not a measure of therapeutic output, and not evidence of benefit.

What eMedica is not

Not a cure, and not a treatment for any named condition: no claim of cure or of clinical efficacy is made for any condition. Not a replacement for prescribed treatment — it is adjuvant, and prescribed medication should be continued unless the treating physician changes it. Not FDA approved and not CE marked: there is no 510(k), De Novo or PMA, no assessment under the EU Medical Device Regulation, and it is not marketed in the United States. Not supported by a published randomised controlled trial; none has been published. And not the same organisation as Emedica Ltd of the United Kingdom, which is a GP examination training company and is unrelated.

Where the patent is granted

The invention is Medical therapeutic device, application 17/753,643, priority from Indian application 201921036412 filed 10 September 2019, granted in the United States on 18 February 2025 as US 12,226,183 B2 with a term running to 5 May 2041.

Corresponding grants are on the registers of Japan (JP 7611901 B2), South Korea (KR 10-2954775), Australia (AU 2020346420 B2), Canada (CA 3150348), Saudi Arabia (SA 18122) and South Africa (ZA 2022/04073 B). Jurisdictions are named rather than counted, deliberately: a count goes stale the moment one member of a family lapses, and a reader cannot check a number. The European application EP 4041064 is under examination — an application, not a grant — and the Indian application is pending.

A patent is a finding on novelty, inventive step and industrial applicability. A patent office does not test whether a device works, and a granted patent is not evidence that it does.

Who should not use it

Physician clearance is required first, and the device should not be used by people with implanted electronic devices such as pacemakers, implantable defibrillators, deep brain stimulators, cochlear implants or implanted pumps; in pregnancy, particularly over the abdomen, lower back or pelvis; over a known tumour site without oncologist direction; over the head and neck in epilepsy or seizure disorder without neurologist guidance; with known or suspected deep vein thrombosis or active thrombophlebitis; or in cardiac arrhythmia or unstable cardiac disease without cardiology clearance. The full page carries the electrode-placement cautions and the stop-and-seek-advice list.

Disclosure. I am the inventor named on the eMedica patent and the founder and CTO of the manufacturer. I have a commercial interest in this device.

Not medical advice. This post describes a device and the documents that govern it. It is not medical advice, not a recommendation for treatment, and not a reason to change any prescribed treatment. eMedica is a non-invasive adjuvant device intended to be used alongside — not instead of — prescribed medication, clinical protocols and medical procedures. Continue prescribed medication unless your treating physician changes it, and consult a qualified healthcare professional before starting or changing any therapy. Individual results may vary.

Read the full version, with references: What eMedica is, precisely. Related: eMedica: the questions, including the answers that are no and the patent register.